Menu
Back to User profile » Dr Beth Hahn
Papers published by Dr Beth Hahn:
Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
Kalhan R, Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, MacKnight SD, Hahn B
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1149-1161
Published Date: 22 April 2021
Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma
Silver J, Bogart M, Packnett E, Wu J, McMorrow D, Hahn B
Journal of Asthma and Allergy 2020, 13:689-699
Published Date: 16 December 2020
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
Moretz C, Hahn B, White J, Goolsby Hunter A, Essoi B, Elliott C, Ray R
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2715-2725
Published Date: 29 October 2020
Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
Moretz C, Cole AL, Mu G, Wu B, Guisinger A, Liu Y, Hahn B, Baylis L
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2207-2215
Published Date: 16 September 2020
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B
Journal of Asthma and Allergy 2020, 13:77-87
Published Date: 29 January 2020
Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol
Moretz C, Bengtson LGS, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2047-2060
Published Date: 4 September 2019
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
Moretz C, Sharpsten L, Bengtson LGS, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:1721-1737
Published Date: 1 August 2019
Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts
Müllerová H, Hahn B, Simard EP, Mu G, Hatipoğlu U
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:683-692
Published Date: 22 March 2019
Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, Ortega H
Journal of Asthma and Allergy 2019, 12:43-58
Published Date: 25 January 2019
Health characteristics of patients with asthma, COPD and asthma–COPD overlap in the NHANES database
Llanos JP, Ortega H, Germain G, Duh MS, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2859-2868
Published Date: 12 September 2018
Burden of disease associated with a COPD eosinophilic phenotype
Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2425-2433
Published Date: 13 August 2018